Clinical Trial Information A Phase II Study of Dose-Dense Gemcitabine Plus Cisplatin (ddGC) in Patients With DNA Muscle-Invasive Bladder Cancer With Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious Damage Response (DDR) Gene Alterations Protocol Number: A031701 Status: Open Age Group: Adult Treatment Type: Treatment Phase: II NCT ID: NCT03609216 Scope Information Scope: National Disease Site(s): Urinary Bladder
